One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Asia-Pacific Contraceptive Drugs and Devices Market

[ 英語タイトル ] Asia-Pacific Contraceptive Drugs and Devices Market - Growth, Trends, and Forecast (2020 – 2025)

Product Code : MDHC0088684
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 80
Category : Healthcare and Pharmaceuticals
Study Area : Asia Pacific
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3750 / Question Form
5 User USD4250 / Question Form
Enterprise User USD7000 / Question Form
 - Bayer AG
- Pfizer Inc.
- Merck & Co. Inc.
- CooperSurgical Inc.
- Allergan PLC
- Johnson & Johnson Ltd
- Lupin Pharmaceuticals Ltd
- Mylan Laboratories
- Church & Dwight Co. Inc.
- The Female Health Company

[Report Description]

The Asia-Pacific contraceptive drugs and devices market is anticipated to record a CAGR of 6.39%, during the forecast period. The major factors attributing to the growth of the Asia-Pacific contraceptive drugs and devices market include the necessity to avoid unwanted pregnancies and their complications. The need to avoid unwanted pregnancies, especially in teenage women, is one of the major drivers for this market. It is also observed that more than half of the women identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain, and acne, as reasons for use. This is also one of the factors contributing to the growth of the market. The other factors helping the growth of the contraceptives market are the increasing incidence of STDs and the rapid increase in population in the region.

Key Market Trends

Oral Contraceptive Segment is Expected to Hold the Largest Market Share in the Asia-Pacific Contraceptive Market

Oral contraceptive pills are seen as the easiest method of contraception in the industry. They act by prohibiting implantation within the uterus if taken within 2-3 days of having unsafe sexual contact. The simplicity of their usage makes them an ideal contraceptive in the market. These are easily marketed across the region by companies, and thus, easily consumed by a large section of the population, regionally. These factors are expected to contribute to the growth of the market during the forecast period.

Competitive Landscape

The Asia-Pacific contraceptive market is competitive and consists of several players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the region. Some of the companies that are currently dominating the market are Bayer AG, Pfizer Inc., Merck & Co. Inc., CooperSurgical Inc., and Allergan PLC.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of the STDs
4.2.2 Increasing Rate of Unintended Pregnancies
4.2.3 Rise in Government Initiatives
4.3 Market Restraints
4.3.1 High Cost of Devices and Treatment
4.3.2 Side Effects Associated with the Use of Contraceptive Drugs and Devices
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 By Drugs Oral Contraceptives Topical Contraceptives Contraceptive Injectable
5.1.2 By Device Condoms Diaphragms Cervical Caps Sponges Vaginal Rings IUD Other Devices
5.2 By Gender
5.2.1 Male
5.2.2 Female
5.3 Geography
5.3.1 Asia-Pacific China Japan India Australia South korea Rest of Asia-Pacific

6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Pfizer Inc.
6.1.3 Merck & Co. Inc.
6.1.4 CooperSurgical Inc.
6.1.5 Allergan PLC
6.1.6 Johnson & Johnson Ltd
6.1.7 Lupin Pharmaceuticals Ltd
6.1.8 Mylan Laboratories
6.1.9 Church & Dwight Co. Inc.
6.1.10 The Female Health Company




Recommended reports